$3.94 Million in Sales Expected for Voyager Therapeutics Inc (NASDAQ:VYGR) This Quarter

Equities analysts predict that Voyager Therapeutics Inc (NASDAQ:VYGR) will post sales of $3.94 million for the current quarter, according to Zacks Investment Research. Four analysts have issued estimates for Voyager Therapeutics’ earnings, with the highest sales estimate coming in at $6.25 million and the lowest estimate coming in at $2.00 million. Voyager Therapeutics reported sales of $2.09 million during the same quarter last year, which indicates a positive year-over-year growth rate of 88.5%. The business is scheduled to issue its next quarterly earnings results on Wednesday, November 6th.

On average, analysts expect that Voyager Therapeutics will report full year sales of $51.70 million for the current financial year, with estimates ranging from $5.00 million to $70.57 million. For the next fiscal year, analysts anticipate that the company will report sales of $51.66 million, with estimates ranging from $7.60 million to $95.57 million. Zacks’ sales averages are a mean average based on a survey of research firms that follow Voyager Therapeutics.

Voyager Therapeutics (NASDAQ:VYGR) last released its quarterly earnings results on Friday, August 9th. The company reported $0.29 EPS for the quarter, beating analysts’ consensus estimates of ($0.88) by $1.17. Voyager Therapeutics had a negative return on equity of 71.08% and a negative net margin of 106.23%. The company had revenue of $46.09 million during the quarter, compared to analysts’ expectations of $5.25 million.

A number of research firms have commented on VYGR. BidaskClub cut Voyager Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, August 7th. HC Wainwright reiterated a “buy” rating and issued a $26.00 price target on shares of Voyager Therapeutics in a research note on Monday, August 12th. Wedbush increased their price target on Voyager Therapeutics from $27.00 to $36.00 and gave the company an “outperform” rating in a research note on Tuesday, June 18th. Nomura reiterated a “buy” rating and issued a $37.00 price target on shares of Voyager Therapeutics in a research note on Tuesday, August 13th. Finally, Morgan Stanley increased their price target on Voyager Therapeutics from $21.00 to $28.00 and gave the company an “equal weight” rating in a research note on Friday, July 12th. One investment analyst has rated the stock with a sell rating, two have given a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $27.50.

Voyager Therapeutics stock traded down $0.83 during midday trading on Wednesday, reaching $19.65. The company’s stock had a trading volume of 337,108 shares, compared to its average volume of 389,768. The stock’s 50-day simple moving average is $22.99 and its 200-day simple moving average is $20.89. Voyager Therapeutics has a 52-week low of $7.76 and a 52-week high of $28.79. The stock has a market capitalization of $782.26 million, a P/E ratio of -7.15 and a beta of 2.55.

Several hedge funds have recently made changes to their positions in VYGR. Clearbridge Investments LLC increased its holdings in shares of Voyager Therapeutics by 93,030.6% in the first quarter. Clearbridge Investments LLC now owns 379,973 shares of the company’s stock valued at $7,273,000 after purchasing an additional 379,565 shares during the period. Invesco Ltd. increased its holdings in shares of Voyager Therapeutics by 643.6% in the second quarter. Invesco Ltd. now owns 421,155 shares of the company’s stock valued at $11,464,000 after purchasing an additional 364,516 shares during the period. Nuveen Asset Management LLC acquired a new position in shares of Voyager Therapeutics in the second quarter valued at about $7,009,000. Renaissance Technologies LLC increased its holdings in shares of Voyager Therapeutics by 48.2% in the second quarter. Renaissance Technologies LLC now owns 729,801 shares of the company’s stock valued at $19,865,000 after purchasing an additional 237,500 shares during the period. Finally, BlackRock Inc. increased its holdings in shares of Voyager Therapeutics by 9.8% in the second quarter. BlackRock Inc. now owns 2,079,554 shares of the company’s stock valued at $56,605,000 after purchasing an additional 185,582 shares during the period. 75.39% of the stock is currently owned by institutional investors and hedge funds.

About Voyager Therapeutics

Voyager Therapeutics, Inc, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trial for the treatment of Parkinson's disease.

Featured Story: Technical Analysis of Stocks, How Can It Help

Get a free copy of the Zacks research report on Voyager Therapeutics (VYGR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Voyager Therapeutics (NASDAQ:VYGR)

Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.